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derivatives by apolipoprotein D: implications for lipid antioxidant activity
and Alzheimer’s disease
Surabhi BHATIA*, Bianca KNOCH†‡, Jenny WONG†‡, Woojin S. KIM*, Paul L. ELSE†§, Aaron J. OAKLEY†¶ and Brett GARNER†‡1
*Neuroscience Research Australia, Sydney, NSW 2031, Australia, †Illawarra Health and Medical Research Institute, University of Wollongong, NSW 2522, Australia, ‡School of
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ApoD (apolipoprotein D) is up-regulated in AD (Alzheimer’s
disease) and upon oxidative stress. ApoD inhibits brain
lipid peroxidation in vivo, but the mechanism is unknown.
Specific methionine residues may inhibit lipid peroxidation by
reducing radical-propagating L-OOHs (lipid hydroperoxides)
to non-reactive hydroxides via a reaction that generates
MetSO (methionine sulfoxide). Since apoD has three conserved
methionine residues (Met49, Met93 and Met157), we generated
recombinant proteins with either one or all methionine residues
replaced by alanine and assessed their capacity to reduce
HpETEs (hydroperoxyeicosatetraenoic acids) to their HETE
(hydroxyeicosatetraenoic acid) derivatives. ApoD, apoDM49-A and
apoDM157-A all catalysed the reduction of HpETEs to their
corresponding HETEs. Amino acid analysis of HpETE-treated
apoD revealed a loss of one third of the methionine residues
accompanied by the formation of MetSO. Additional studies
using apoD(M93-A) indicated that Met93 was required for
HpETE reduction. We also assessed the impact that apoD
MetSO formation has on protein aggregation by Western blotting
of HpETE-treated apoD and human brain samples. ApoD
methionine oxidation was associated with formation of apoD
aggregates that were also detected in the hippocampus of
AD patients. In conclusion, conversion of HpETE into HETE
is mediated by apoD Met93, a process that may contribute to apoD
antioxidant function.
Key words: Alzheimer’s disease, antioxidant, apolipoprotein D
(apoD), lipid peroxidation, methionine oxidation.
INTRODUCTION
ApoD (apolipoprotein D) is a lipid-binding lipocalin that is
thought to play a role in the transport of specific hydrophobic
molecules, notably progesterone and arachidonic acid, in the brain
and peripheral circulation [1]. ApoD expression is increased in
the aging brain and in neuropathological conditions including
schizophrenia, AD (Alzheimer’s disease) and Parkinson’s disease,
but the reasons for this remain unclear [2–7]. Increased lipid
peroxidation and up-regulation of antioxidant gene expression are
common features in these conditions. A previous study revealed
that apoD protects against lipid peroxidation in the brain [8].
Studies in mice showed that cerebral apoD expression is increased
in response to Paraquat-induced oxidative stress, that cerebral
lipid peroxidation is increased in apoD-null compared with wild-
type animals and that overexpression of human apoD prevents
cerebral lipid peroxidation [8]. In addition, expression of human
apoD reduced the accumulation of aldehydic end-products of
lipid peroxidation in an aged Drosophila model [9]. Even though
several lines of evidence demonstrate that apoD protects against
lipid peroxidation in the brain, the mechanisms underlying this
action remain to be defined.
Previous studies have firmly established the antioxidant
function of protein methionine residues [10]. The pathway
involves the selective oxidation of methionine residues by a
variety of reactive species to generate MetSO (methionine
sulfoxide) [11]. MetSO may be reduced back to methionine by
MSRs (MetSO reductases) that are in turn redox-cycled back
to their reduced state by thioredoxin [12,13]. In the case of
lipid peroxidation, it is known that specific methionine residues
of plasma apolipoproteins apoA-I and apoA-II interact with L-
OOHs (lipid hydroperoxides) to yield non-reactive L-OHs (lipid
hydroxides) and MetSO [14]:
L-OOH + Met → L-OH + MetSO (1)
This two-electron reduction of L-OOH to L-OH competes
with transition metal-catalysed Fenton-type reactions (e.g. one-
electron transfers generating lipid alkoxyl radicals, L-O•) that
accelerate lipid peroxidation [15]:
L-OOH + Fe2+/Cu1+ → L-O• +−OH + Fe3+/Cu2+ (2)
The methionine/L-OOH reaction [see eqn (1)] thereby prevents
the propagation of lipid peroxidation that would otherwise be
caused by L-O•-mediated abstraction of bis-allylic hydrogen
atoms from proximal lipid acyl chains. This reaction pathway
explains a significant proportion of the lipid antioxidant
capacity associated with plasma HDL (high-density lipoprotein)
apolipoproteins [14,15]. On the basis of these studies and the
previously discovered in vivo role of apoD as a lipid antioxidant
[8,9], we were prompted to examine the role that apoD methionine
Abbreviations used: AD, Alzheimer’s disease; apo, apolipoprotein; AQC, 6-aminoquinolyl-N-hydroxysuccinimidyl carbamate; CHO, Chinese-hamster
ovary; CHO-apoD, CHO-K1 cells stably expressing apoD; GdnHCl, guanidinium chloride; HDL, high-density lipoprotein; HEK, human embryonic
kidney; HETE, hydroxyeicosatetraenoic acid; HMW, high molecular mass; HpETE, hydroperoxyeicosatetraenoic acid; L-OH, lipid hydroxide; L-OOH,
lipid hydroperoxide; MetSO, methionine sulfoxide; MSR, MetSO reductase; PC, phosphatidylcholine; PLA2, phospholipase A2; RT, retention time; t-BOOH,
t-butyl hydroperoxide; TBS, Tris-buffered saline; THF, tetrahydrofuran.
1 To whom correspondence should be addressed (email brettg@uow.edu.au).
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residues may play in the reduction of L-OOH to L-OH [see eqn
(1)]. The results of the present study indicate that apoD Met93
reduces a variety of fatty acid L-OOHs to their corresponding L-
OHs and that this is associated with lipid antioxidant capacity.
The concomitant formation of MetSO results in an increased
propensity for apoD self-association to yield aggregates that
are similar to those detected in the insoluble fraction of human
hippocampal homogenates from AD patients. The present study
provides important insights into the mechanisms by which apoD
may protect against lipid peroxidation in the brain.
MATERIALS AND METHODS
Materials
All HETEs (hydroxyeicosatetraenoic acids) and HpETEs (hy-
droperoxyeicosatetraenoic acids) were purchased from Cayman
Chemicals. Analytical grade ethanol, TFA (trifluoroacetic
acid), THF (tetrahydrofuran), acetic acid, urea and GdnHCl
(guanidinium chloride) were purchased from Sigma. HPLC-
grade acetonitrile and propan-2-ol were purchased from Ajax
Chemicals. Cell culture media and additives were purchased from
Invitrogen.
Protein expression and purification
Human apoA-I (GenBank® accession number NM_000039.1)
and apoD (GenBank® accession number NM_001647.3) were
expressed in human HEK (human embryonic kidney)-293 cells
using the pcDNA3.1( + ) vector. A linker, FLAG-tag and poly-
His tail (SGGGGSDYKDDDDKHHHHHH) was included at the
C-terminus and the secreted proteins were purified using a Ni-
HiTrap column with a linear gradient from 20–500 mM imidazol
in PBS and 500 mM NaCl. All proteins were >95% pure as
demonstrated by a single Coomassie Brilliant Blue-stained band
at the predicted size in PAGE gels that also corresponded to the
correct product as assessed by Western blotting. The purified
proteins were dialysed against PBS and stored at − 80 ◦C.
Protein/HpETE incubation conditions
Apolipoproteins (0.5 mg/ml) were incubated in PBS with H2O2
(0.1 or 1.0 M), or the indicated HpETEs (0.05 mg/ml) for periods
of up to 8 h. At the indicated time points aliquots of the samples
were removed and the protein fraction precipitated with 9 vol.
of ice-cold ethanol for 1 h at − 20 ◦C. The samples were then
centrifuged at 16000 g for 5 min at 4 ◦C. The ethanol fraction was
removed (and analysed for lipid where appropriate), whereas the
apolipoprotein pellet was dried under vacuum and re-suspended
in 20 μl of PBS in preparation for HPLC analysis.
HPLC analysis of lipids and proteins
Eicosatetraenoic acid-derived L-OOHs (40 μl aliquots) were
analysed using a 5 μm, 25 cm×0.46 cm, C18 reversed-phase
column at a flow rate of 1 ml/min at 22 ◦C. The mobile
phase used to achieve separation of hydroxy and hydroperoxy
derivatives of eicosatetraenoic acid was 0.1% acetic acid
in H2O/acetonitrile/THF [45:45:10, by vol.] with UV236 nm
absorbance detection. Ethanol precipitated apoD (18 μl in PBS)
was analysed by reversed-phase HPLC after the addition of
54 μl of 6 M GdnHCl. Analysis was achieved using a 5 μm,
25 cm×0.46 cm, C18 protein and peptide column (Vydac) and
35–55% acetonitrile gradient containing 0.1% tetrafluoroacetic
acid, over 20 min, at 1 ml/min at 22 ◦C with UV214 nm
absorbance detection.
Protein extraction from brain tissues
Human brain tissue was obtained from the Sydney Brain Bank and
the New South Wales Tissue Resource Centre with ethics approval
from the University of New South Wales Human Research Ethics
Committee. This research was carried out in accordance with the
Declaration of Helsinki (2000) of the World Medical Association.
Tissue samples were obtained from three normal (control) and
three cases of AD brain clinically and pathologically defined
using National Institute on Aging-Reagan criteria as described
previously [16]. The demographic and basic clinical data for
these samples is provided as supplementary data (Supplementary
Table S1 at http://www.BiochemJ.org/bj/442/bj4420713add.htm).
The age, PMIs (post-mortem intervals) and tissue pH were not
significantly different between the groups: 80 +− 7 years compared
with 83 +− 0.3 years; 15 +− 3 h compared with 14 +− 6 h; and
pH 6.7 +− 0.2 compared with pH 6.3 +− 0.03, for control compared
with AD samples respectively (all data means +− S.E.M.).
Fractions of homogenized human hippocampus that were
insoluble in TBS (Tris-buffered saline) and TBS containing 1 %
(v/v) Triton X-100 detergent were extracted from control (n = 3)
and AD (n = 3) cases using GdnHCl as described previously
[17]. GdnHCl was removed from tissue samples by ethanol
precipitation as described previously [17]. Since the total protein
levels in the GdnHCl fraction can vary when comparing control
and AD samples, protein concentrations were determined by
BCA (bicinchoninic acid) assay and equal amounts of protein
were re-suspended in loading dye, separated on 8% PAGE gels
and transferred on to 0.45 μm nitrocellulose membranes at 100 V
for 30 min. The membranes were blocked in 5% non-fat dried
milk in PBS for 2 h at 22 ◦C then probed with an anti-apoD mouse
monoclonal antibody (1:1000 dilution; Sapphire Biosciences)
overnight at 4 ◦C followed by incubation with horseradish
peroxidase-conjugated rabbit anti-mouse (1:5000 dilution)
polyclonal antibody for 1 h at 22 ◦C. The membranes were was-
hed and protein was detected using enhanced chemiluminescence
and X-ray film. The membranes were stripped and re-probed
for β-actin (1:2000 dilution; Sigma) to confirm equal protein
loading.
ApoD amino acid analysis using enzymatic hydrolysis
Methionine and MetSO were determined using enzymatic
hydrolysis to release the amino acids from the protein followed
by quantification using a pre-column derivatization reversed-
phase HPLC procedure. The amino acids were derivatized
with AQC (6-aminoquinolyl-N-hydroxysuccinimidyl carbamate)
reagent [18] and analysed using an Acquity UPLC system (Waters
Corporation) with a 2.1 mm×150 mm, 1.7 μm, reversed-phase
C18 column (Acquity UPLC BEH130, Waters). The enzyme
digestion was based on a procedure developed to analyse MetSO
in milk proteins [19]. In brief, protein samples (20 μg) were
dissolved in 50 μl of Hepes buffer (0.1 M, pH 7.5) and subjected
to a single-pot three-enzyme digestion using pronase E (2.5 μl),
leucine aminopeptidase M (1 μl) and prolidase (0.5 μl) for 20 h
at 37 ◦C. Each of the enzymes was prepared at 2 mg/ml and an
enzyme blank was included. After the addition of an internal
standard (norvaline), the digest mix was derivatized with AQC
reagent using the AccQTag Ultra derivatization kit (Waters).
MetSO and methionine sulfone standards were clearly separated
using this method [RTs (retention times) of 5.55 min and 5.85 min
respectively] and this was sufficient to exclude the possibility that
the MetSO peak derived from the samples was contaminated with
methionine sulfone.
c© The Authors Journal compilation c© 2012 Biochemical Society
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Liposome autoxidation
The liposome system consisted of 1 mg/ml total L-α PC
(phosphatidylcholine) (95 %) derived from soy (Avanti Polar
Lipids). The phospholipid was prepared from a 10 mg/ml stock
solution [in 2:1 (v/v) chloroform/methanol], and evaporated under
nitrogen at 37 ◦C for 1 h until dry. The resulting film was hydrated
in 140 mM NaCl and mixed by vortexing for 10 min at 37 ◦C.
A Sanyo Soniprep 150 probe-type sonicator was then used
(amplitude of 10 microns for three lots of 45 s on ice) to form
small unilamellar vesicles. After liposome preparation, 10 μg/ml
(final) of apoD (wild-type or all methionine-to-alanine mutants)
was added to the liposome preparation. These additives were
made up in PBS and diluted 1:10 into the liposome preparations.
The control liposome conditions contained an equivalent amount
(0.1 vol.) of PBS. The liposomal preparations were incubated
at 37 ◦C for 24 h. Note that an exogenous radical initiator was
not added in this assay to avoid direct inhibition/scavenging by
the added proteins.
L-OOHs in the liposomes were measured by Fe2 + oxidation
using the xylenol orange assay in samples collected at 0 h and
24 h. A 50 μl aliquot of sample was taken from the liposomal
preparation at each time point and 900 μl of xylenol orange
reagent (1 mM butylated hydroxytolulene, 0.25 mM ammonium
ferrous sulfate, 0.25 mM sulfuric acid and 100 μM xylenol
orange) was added. The samples were incubated with the reagent
for 50 min, and the absorbance was read at 560 nm. A standard
curve was generated using t-BOOH (t-butyl hydroperoxide).
ApoD stable cell lines
CHO (Chinese-hamster ovary)-K1 cell lines expressing wild-
type apoD or apoDM–A mutant were generated as described
in Supplementary Online Data (at http://www.BiochemJ.org/
bj/442/bj4420713add.htm). For continuous culture, CHO cells
stably expressing wild-type or mutant apoD were cultured in
CHO-K1 growth medium supplemented with 400 μg/ml G418.
To determine if apoD could act as a cellular lipid antioxidant,
non-transfected CHO cells and wild-type apoD and apoDM–A
mutant cells were seeded in 96-well plates at a density of 1×105
cells/well. After 24 h the cells were incubated with vehicle (0.1 %
ethanol) or 50 μM t-BOOH for 24 h to induce cellular lipid
peroxidation. After treatment, the culture medium was removed
and cell monolayers were washed twice with PBS and assayed
directly for L-OOH using the xylenol orange PeroxiDetectTM kit
(Sigma, catalogue number PD1) according to the manufacturer’s
instructions.
Statistics
Unless otherwise noted, experiments were routinely repeated at
least twice in either duplicate or triplicate conditions. Statistical
significance was assessed using the two-tailed Student’s t test for
unpaired data with P < 0.05 considered significant. For multiple
comparisons, differences between groups were analysed using a
one-way ANOVA with post-hoc analysis using Tukey’s test.
RESULTS
Reversed-phase HPLC RT of recombinant apoA-I and apoD (but not
methionine-to-alanine mutants) is reduced by exposure to H2O2
In order to assess the role that apoD methionine residues may
play in L-OOH reduction, we utilized a human HEK-293 cell
expression system to generate recombinant proteins. Owing to
Figure 1 Methionine residues are required for the H2O2-mediated decrease
in apoA-I and apoD hydrophobicty assessed by reversed-phase HPLC
(A) Recombinant human wild-type (WT) and all methionine-to-alanine mutant (M–A) apoA-I
and apoD were analysed by Western blotting. Samples were loaded at 1.0 μg and 0.5 μg per
lane as indicated. Positions of molecular mass markers are indicated on the left-hand side. (B)
ApoA-I was incubated in PBS (black line), with 0.1 M H2O2 (grey line) or 1.0 M H2O2 (broken
line) for 1 h at 22◦C and assessed by HPLC. Note that the black and grey lines overlap in the
apoA-IM–A panel. (C) ApoD was incubated in PBS (black line) or with 0.1 M H2O2 in PBS (grey
line) for 1 h at 22◦C and assessed by HPLC.
the introduction of an oxygen atom in the methionine side
chain, formation of MetSO in native apolipoproteins can be
measured by a reduction in reversed-phase HPLC RTs [15,20].
To confirm that conversion of methionine into MetSO in proteins
purified using this method (based on nickel purification via
a C-terminal histidine tag) exhibit changes in HPLC RT that
are comparable with changes observed in native proteins, we
first synthesized human wild-type apoA-I and a mutant form
of the protein in which the three methionine residues (Met86,
Met112 and Met148) were replaced by alanine (apoA-IM–A). Both
the wild-type and mutant forms of the protein were secreted
and detected at the predicted molecular mass of ∼29 kDa
(Figure 1A). Treatment of apoA-I with either 1.0 M or 0.1 M
H2O2 for 1 h resulted in a dose-dependent reduction in RT
(Figure 1B) that was in very close agreement to previous results
obtained using human plasma-derived apoA-I [15,20]. In contrast,
the RT for apoA-IM–A was not changed by H2O2 treatment,
thereby confirming the specificity of this change to oxidation
of methionine residues (Figure 1B). In agreement with earlier
studies using HDL-derived apoA-I [14], the metal chelator EDTA
did not inhibit the shift in RT associated with recombinant
apoA-I methionine oxidation (Supplementary Figure S1A
c© The Authors Journal compilation c© 2012 Biochemical Society
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at http://www.BiochemJ.org/bj/442/bj4420713add.htm). This is
consistent with a direct two-electron oxidation of methionine
by H2O2 [14,20]. We then conducted similar experiments using
recombinant apoD. Human apoD contains three methionine
residues (Met49, Met93 and Met157). Both wild-type apoD and
mutant apoD with all of the methionine residues replaced by
alanine (apoDM–A) were secreted as glycoproteins and detected at
the predicted molecular mass of ∼30 kDa (Figure 1A). Treatment
of recombinant apoD with PNGase F (peptide N-glycosidase F)
yielded deglycosylated products at a molecular mass of ∼22 kDa
(Supplementary Figure S1B), consistent with the loss of two
complex N-glycans from Asn45 and Asn78 [21]. HPLC analysis of
apoD revealed a series of partially resolved peaks that are most
likely due to apoD N-glycan heterogeneity [21,22]. Treatment
of apoD with 0.1 M H2O2 for 1 h reduced the apoD RT, whereas
there was no impact on apoDM–A treated under identical conditions
(Figure 1C). Although the magnitude of change in apoD RT
induced by H2O2 was less than observed with apoA-I (compare
Figures 1B and 1C), the method did provide a high level of
precision which was utilized to examine the possible conversion
of apoD methionine into MetSO by L-OOH.
ApoD (but not an apoD all methionine-to-alanine mutant)
catalyses the reduction of 5s-, 12s- and 15s-HpETEs to their
respective HETEs
Products of lipoxygenase-mediated arachidonic acid oxidation
(5s-, 12s- and 15s-HpETEs) were investigated as these L-OOHs
are highly relevant to brain oxidative stress and inflammation
[23]. Incubation of apoD with 15s-HpETE resulted in a decrease
in apoD HPLC RT, whereas there was no impact on apoDM–A
treated under identical conditions (Figure 2A). ApoD accelerated
the conversion of 15s-HpETE into the corresponding L-OH (15s-
HETE) as assessed by HPLC (Figure 2B), whereas there was very
little conversion of 15s-HpETE into 15s-HETE in the presence
of apoDM–A (Figure 2B). The rate of L-OOH reduction by apoD
declined after the 1 h time point and this may be due to the
consumption of methionine residues in the early phase of
the incubation (Figure 2C).
To examine the specificity of apoD for HpETE reduction,
a series of experiments were conducted using 15s-, 12s- and
5s-HpETE. ApoD efficiently converted all HpETEs into their
corresponding HETEs (Figure 3). There were no significant
differences in the extent of HpETE reduction observed when
comparing the different substrates (although a trend for
accelerated reduction of 5s-HpETE was noted). Incubation of
15s-HETE with apoD did not result in a significant change in 15s-
HETE concentration compared with the PBS 15s-HETE control
incubation (Figure 3). These data indicate that apoD can reduce
the major lipoxygenase-derived reactive L-OOHs to relatively
inert L-OHs and that the reaction is dependent on one or more
apoD methionine residues.
ApoD (but not an apoD all methionine-to-alanine mutant) inhibits
liposome autoxidation and cell-associated lipid peroxidation
induced by t-BOOH
To further investigate the potential antioxidant activity of apoD,
we used a soy PC liposome autoxidation system. Autoxidation of
soy PC liposomes is a reliable means for investigating antioxidant
action [24,25]. Soy PC liposomes have a fatty acid content of
approximately 15% C16:0 (palmitic), 4% C18:0 (stearic), 11 % C18:1
(oleic), 63% C18:2 (linoleic), 6% C18:3 (linolenic) and 1% other
fatty acids. The major target for autoxidation is therefore C18:2.
In agreement with the data derived from the HpETE reduction
Figure 2 ApoD methionine residues are required for reduction of 15s-HpETE
to 15s-HETE
ApoD (0.5 mg/ml) was incubated with 15s-HpETE (0.05 mg/ml) in PBS at 37◦C. At the indicated
times samples were collected and the protein and lipid fractions were separated and analysed
by HPLC. (A) ApoD and apoDM–A (in which all methionine residues were replaced by alanine)
analysis after incubation with 15s-HpETE at t = 0 h (black line), after 1 h (grey line) or 4 h
(broken line). (B) HPLC analysis of the lipid fractions from the samples described in (A)
(same line styles for time intervals). 15s-HpETE elutes at 29.5 min, whereas 15s-HETE elutes at
25.3 min. The pie chart inserts illustrate the proportion of 15s-HpETE (dark grey) and 15s-HETE
(light grey) present at the 4 h time point. (C) Changes in 15s-HpETE and 15s-HETE are plotted
and compared with PBS control conditions. Data are means of duplicate samples from a single
experiment where the error bars (range) are smaller than the symbols for all samples. The
experiment was repeated six times using different HpETEs and time course conditions and all
yielded similar results. p.a.u., peak area units.
experiments, apoD inhibited liposome lipid peroxidation more
effectively than did apoDM–A (Figure 4A). We also assessed the
capacity for apoD to act as a cellular lipid antioxidant. When CHO
cells were treated with 50 μM t-BOOH) for 24 h, total cellular
L-OOH levels were increased by 17% (P < 0.05) compared with
non-treated cells, whereas there were no significant changes
in cellular L-OOH levels induced by t-BOOH in CHO-apoD
(CHO cells that stably express apoD) compared with non-treated
CHO-apoD cells (Figure 4B). This protective effect of apoD
was not detected in CHO cells that stably expressed apoDM–A
(CHO-apoDM–A) where t-BOOH treatment resulted in a 22 %
increase (P < 0.01) in cellular L-OOH compared with non-treated
CHO-apoDM–A cells (Figure 4B). The basal levels of cellular L-
OOH were not reduced in the CHO-apoD cells compared with
c© The Authors Journal compilation c© 2012 Biochemical Society
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Figure 3 Comparison of apoD-mediated conversion of 5s-, 12s- and
15s-HpETE into their corresponding HETEs
ApoD (0.5 mg/ml) was incubated with the HpETEs or 15s-HETE indicated (0.05 mg/ml) for 1 h
in PBS at 37◦C. At the end of the incubation the HpETEs (black bars) and HETEs (grey bars) were
analysed by HPLC. The lipid structures are shown above the histograms. For the incubations
containing HpETEs, the levels of HpETE and HETE present in the PBS at the beginning (t = 0 h) of
the incubation period are indicated by the broken black lines and broken white lines respectively.
Data are means of duplicate samples where the error bars indicate the range. The experiment
was repeated 11 times using different HpETEs and time course conditions and all yielded similar
results. p.a.u., peak area units.
non-transfected CHO cells (Figure 4B). This may be due to the
fact that the vast majority of apoD is secreted and thereby unable
to protect against endogenous intracellular oxidative reactions.
ApoD Met93 is required to reduce HpETEs to their respective
HETEs via a processes that generates MetSO
We next investigated which of the three apoD methionine residues
may be involved in L-OOH reduction. To address this issue
we generated recombinant proteins in which each of the three
apoD methionine residues were individually replaced by alanine
(apoDM49–A, apoDM93–A and apoDM157–A) and assessed these for
L-OOH-reducing activity (in comparison with both apoD and
apoDM–A). All mutant proteins were correctly synthesized and
secreted at the predicted molecular mass (Figure 5A). Both
the apoDM49–A and apoDM157–A, mutants efficiently reduced 5s-
HpETE to 5s-HETE and in both cases this was associated with
a decrease in mutant apoD RT consistent with MetSO formation
(Figure 5B). In stark contrast, apoDM93–A was deficient in L-OOH-
reducing activity (similar to the apoDM–A) and its RT was not
significantly altered by incubation with 5s-HpETE (Figure 5B).
These experiments indicate that apoD Met93 is the primary
methionine residue involved in L-OOH reduction.
To confirm that the reduction of L-OOH by apoD was associated
with methionine conversion into MetSO, we used a sensitive
and specific amino acid analysis method that utilises a protease
Figure 4 ApoD inhibits lipid peroxidation more efficiently than apoDM–A
(A) Liposomes were prepared from PC and wild-type apoD (WT) or mutant apoD in which
all of the methionine residues were replaced by alanine (M-A), and were added to a final
concentration of 10 μg/ml. Samples were then taken at 0 h (black bars) and 24 h (grey bars)
and the amount of L-OOH present measured using the Fe2 + xylenol orange assay was assessed
and compared with control liposome conditions that contained no protein additive (Con). The
relative antioxidant capacity at 24 h was compared between groups by ANOVA and found to
be significant (P < 0.0001). Post-hoc analysis by Tukey’s test indicated significant differences
between all pairs. ###P < 0.0001; ##P < 0.001. (B) CHO-K1 cells that stably express wild-type
apoD (WT) or apoDM–A mutant (M-A) were treated as indicated without t-BOOH (black bars) or
with 50 μM t-BOOH (grey bars) for 24 h to induce cellular lipid peroxidation after which the cell
monolayers were assayed for L-OOH levels using the Fe2 + xylenol orange assay and compared
with control cells (Con) that did not express human apoD. The experiments were repeated twice
using similar conditions and yielding similar results. *P < 0.05; **P < 0.01.
mixture for full protein hydrolysis. This approach overcomes
problems associated with artefactual methionine oxidation that
may occur as a result of gas-phase chemical protein hydrolysis
and electrospray ionization MS methods [19,26]. The amino acid
analysis indicated that after a 1 h incubation period, reduction of
either 5s- or 15s-HpETE to their respective HETEs was associated
with an increase in MetSO levels to account for approximately
one-third (37%) of the total methionine (MetSO + Met) in
wild-type apoD (Figure 6). When apoDM49–A and apoDM157–A
were assessed under the same conditions, approximately half
of the methionine was converted into MetSO (48% and 45%
respectively; Figure 6). In contrast, the interaction of apoDM93–A
with these HpETEs resulted in conversion of only 10% of
methionine into MetSO (Figure 6). This further indicates that
Met93 is the primary methionine residue involved in L-OOH
reduction and that as a result of this reaction MetSO is generated. It
is noteworthy that methionine sulfone (a further oxidation product
of MetSO) was well separated from MetSO in our HPLC method
and was not detected in any of the samples (results not shown).
This indicates that a two-electron transfer is the most likely
mechanism by which apoD reduces L-OOH to L-OH. Standard
gas-phase HCl hydrolysis of the proteins indicated that the stable
amino acids (i.e. excludes tryptophan, cysteine and methionine)
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Figure 5 ApoD Met93 is required for HpETE reduction
(A) Recombinant human single methionine-to-alanine apoD mutants were analysed by Western
blotting. Samples were loaded at 1.0 μg and 0.5 μg per lane as indicated. Positions of molecular
mass markers are indicated on the left-hand side. (B) Wild-type apoD and the indicated apoD
mutants (0.5 mg/ml) were incubated with 15s-HpETE (0.05 mg/ml) for 4 h in PBS at 37◦C (grey
line) and compared with incubation in PBS alone (black line) by HPLC. The pie chart inserts
illustrate the proportion of 15s-HpETE (dark grey) and 15s-HETE (light grey) present at the 4 h
time point. A PBS control that contained 15s-HpETE, but no apoD, is also included (PBS). HPLC
data are from single samples representative of triplicates. 15s-HpETE and 15s-HETE data are
mean values derived from triplicates. The S.E.M. for all HpETE and HETE samples was <1.0 %.
The experiments using apoD methionine-to-alanine single mutants were repeated four times
and all yielded similar results. The experiments using apoD and apoDM–A were repeated six
times and all yielded similar results. The x- and y-axis labels are identical for all plots.
were recovered in the expected amounts with no changes
induced by incubation with HpETE (Supplementary Table S2
at http://www.BiochemJ.org/bj/442/bj4420713add.htm). Other
amino acid side chains (e.g. valine, tyrosine, threonine and
phenylalanine) that may be oxidized by free radicals [27] were
therefore not affected by HpETE treatment. This provides further
evidence that apoD-mediated reduction of L-OOH to L-OH is
specific to methionine residues.
ApoD MetSO generated as a consequence of HpETE reduction
induces apoD dimerization and aggregation
A recent study revealed that oxidation of apoA-I methionine to
MetSO leads to aggregation of the protein into fibrils [28]. We also
Figure 6 ApoD MetSO content assessed by enzymatic hydrolysis and HPLC
ApoD (0.5 mg/ml) was incubated at 37◦C for 4 h in PBS or either 15s- or 5s-HpETE (0.05 mg/ml)
in PBS as indicated. Protein was isolated from lipid by ethanol precipitation and methionine and
MetSO were determined using enzymatic hydrolysis and reversed-phase HPLC. The amount
of MetSO in each sample is expressed as a percentage of total methionine (Met + MetSO).
The number of samples analysed in each experiment (equal for both +− HpETE) was wild-type
(WT), n = 4; M49-A, n = 3; M93-A, n = 6; and M157-A, n = 3. Data are means with S.E.M.
shown by the error bars. Statistical difference comparing each of the mutants to wild-type was
determined by Student’s t test for the HpETE conditions only. **P < 0.01. n.d., not detected.
assessed apoD for the formation of aggregates using SDS/PAGE
and Western blotting. Incubation of apoD with 5s-HpETE for up
to 8 h resulted in a time-dependent formation of dimerized apoD
that was present at only low levels in parallel incubations using
apoDM-A (Figure 7A). As extended incubation periods can cause
most proteins to aggregate [29], we pre-exposed apoD, apoDM–A
and apoDM93–A to 5s-HpETE for 1 h (to oxidize methionine
residues where relevant), separated the protein from the lipid, and
then extended the incubation of the re-isolated apoD for a further
72 h at 37 ◦C. In the absence of 5s-HpETE treatment, ∼15% of
apoD was converted into a dimer at the end of the incubation
period (Figure 7B). Similarly, low or undetectable levels of apoD
aggregates were present in apoDM93–A and apoDM–A in the absence
of 5s-HpETE pre-treatment (Figure 7B). In contrast, pre-treatment
with 5s-HpETE induced the formation of dimers, trimers and
HMW (high molecular mass; >250 kDa) aggregates in apoD,
whereas these HMW aggregates were not present in either the
apoDM93–A or apoDM–A samples, and the levels of dimer and trimer
were substantially reduced in the apoDM–A sample (Figure 7B).
These data indicate that apoD methionine oxidation that occurs as
a consequence of L-OOH reduction promotes apoD aggregation
and that with extended incubation times (e.g. 3 days) methionine
residues in addition to Met93 may also become modified and
contribute to apoD aggregation.
ApoD dimers are present in the hippocampus of AD patients
Previous studies of healthy control post-mortem brain samples
(across a broad range of ages) as well as patients with AD and
schizophrenia did not detect aggregated apoD [3–5]. These studies
all used simple phosphate or Tris buffers during homogenization
which may not be sufficient to extract less-soluble protein
aggregates. We therefore used an established GdnHCl extraction
method that extracts less-soluble proteins from aged brain tissue
[17] to probe for the presence of apoD aggregates in human
hippocampal samples taken from both control and AD cases.
This analysis indicated that apoD was predominantly detected as
a dimerized aggregate in the GdnHCl-extracted fraction of the AD
tissues (Figure 7C). On the basis of the known increase in brain
lipid peroxidation that occurs in AD [30–33], and the results in
the present paper, it is plausible that L-OOH interacts with apoD
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Figure 7 Formation of apoD aggregates in vitro and their identification in
AD hippocampus
(A) Wild-type (WT) and mutant (M-A) apoD (0.5 mg/ml) was incubated with 5s-HpETE
(0.05 mg/ml) in PBS at 37◦C for up to 8 h. At the indicated times the samples were assessed
by Western blotting. (B) Using the same initial conditions described in (A), lipid fractions were
removed from apoD/ apoD mutants (or mock-extracted where no 5s-HpETE was added) after
1 h incubation. The proteins were then redissolved in PBS and incubated for a further 72 h
at 37◦C. After 72 h the samples were assessed by Western blotting. (C) GdnHCl-extracted
proteins from control (Con) and AD hippocampal homogenates were assessed for apoD by
Western blotting after controlling for equal total protein loading. Similar levels of β-actin were
detected across all fractions after stripping and reprobing the blots. Positions of molecular mass
markers are indicated on the left-hand side. Positions of apparent monomer, dimer, trimer and
HMW oligomer (HMW Olig.) forms of apoD are indicated on the right-hand side.
in the AD brain and this results in apoD methionine oxidation
that may contribute to the formation of apoD aggregates and their
accumulation in amyloid plaques.
ApoD dimers generated as a consequence of HpETE reduction
are dissociated by 5 M urea
The precise nature of the apoD aggregates we have detected is
unknown, but the fact that apoD aggregates in AD brain were
stable in 5 M GdnHCl could suggest covalent intermolecular
cross-linking. In a final set of experiments, apoD dimers
Figure 8 ApoD dimerization can be reversed by treatment with 5 M urea,
but not 5 M GdnHCl
ApoD (0.5 mg/ml) was incubated with PBS or 15s-HpETE (0.05 mg/ml) in PBS at 37◦C for 4 h.
The samples were collected and the protein separated from the lipid fractions and incubated
with either 5 M GdnHCl (A) or 5 M urea (B) for 1 h at 37◦C, as indicated, before Western blot
analysis. Positions of molecular mass markers are indicated on the left-hand side.
that were generated in vitro after 4 h incubation with 15s-HpETE
were analysed by Western blotting both in the absence of strong
denaturants and after treatment with either 5 M GdnHCl or 5 M
urea. The apoD dimer was stable in 5 M GdnHCl, but almost
completely dissociated by 5 M urea. This indicates that the apoD
dimer generated in vitro is not due to covalent intermolecular
cross-linking. We acknowledge the possibility that the formation
of HMW oligomers resulting from 72 h incubation of apoD
with HpETEs (Figure 7B) may result in additional types of
intermolecular association that could include covalent cross-
linking.
DISCUSSION
The present study demonstrates that apoD catalyses the reduction
of HpETEs to their corresponding HETEs and that this reaction
is dependent on a single methionine residue at position 93. We
suggest that this L-OOH-reducing activity may contribute to the
lipid antioxidant function of apoD in the brain and, as is the
case with other antioxidant proteins [3,34], this would help to
explain why apoD expression is up-regulated under conditions
associated with increased cerebral lipid peroxidation such as aging
and AD [3,5,6]. Although the precise mechanism involved in the
reduction of HpETEs to HETEs by apoD Met93 is not known,
we suggest that it may involve a direct two-electron reduction
of L-OOH to L-OH; as has been reported previously for the
interaction of specific methionine residues of plasma apoA-I
and apoA-II with HDL-associated L-OOH [15]. One caveat in
this hypothesis is that the amount of L-OOH converted into L-
OH typically exceeds the protein methionine concentration and
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it is thus possible that additional mechanisms may play a role.
Regardless of this issue, our data clearly indicate that apoD Met93
selectively catalyses the reduction of HpETEs to their HETE
derivatives. The interaction of HpETEs with apoD Met93 may
be particularly relevant in the AD brain where the activity of the
group IVA PLA2 (phospholipase A2) that cleaves arachidonic acid
from the sn-2 position of membrane phospholipids is increased
along with up-regulation of 5-, 12- and 15-lipoxygenase activity
[5,6,31,35,36].
Non-enzymatic free radical-mediated lipid peroxidation may
also play a role in AD and there is evidence that the amyloid-β
peptide itself promotes neuronal membrane lipid peroxidation
[32,37]. Even though such oxidized phospholipid fatty acids
are preferred substrates for cleavage by PLA2 [38] (and would
therefore be likely to be released from cellular membranes as free
fatty acid hydroperoxides relatively soon after they are generated),
our data indicating that apoD also inhibits liposome phospholipid
peroxidation suggests that docking of the released L-OOH within
the binding pocket is not strictly required for apoD antioxidant
activity. It is possible that the hydrophobic surface that contains
apoD Met93 [39] may interact with cellular lipid membrane sur-
faces (from which L-OOH may protrude [40]) in order to convert
potential radical-generating L-OOH into relatively inert L-OH
and thereby inhibit membrane lipid peroxidation chain reactions.
In addition to the role that apoD may play as an antioxidant
in the brain, the apoD-mediated modulation of eicosanoid
metabolism through conversion of HpETEs into HETEs may also
influence inflammatory pathways. For example, the modulation
of the 5-HpETE to 5-HETE ratio regulates the synthesis of
downstream inflammatory leukotrienes LTC4 and LTB4 [23,41].
It is also clear that many HpETEs and HETEs exhibit distinct
biological activities in the brain, including regulation of synaptic
function and cerebrovascular permeability [23]. For example, 5s-
HpETE potently inhibits (IC25 = 10− 8 M) neuronal Na+ /K+ -
ATPase activity (important for the maintenance of neuronal
excitability and synaptic transmission), whereas the reduced
product, 5s-HETE, has no impact [42].
Similar to solvent exposed methionine residues in other
proteins, apoD Met93SO is probably rapidly reduced to methionine
by MSR expressed in the brain. This would be predicted
to maintain the antioxidant function of apoD [12,13]. Under
conditions associated with depletion of MSR activity or high
levels of lipid peroxidation, the failure of apoD Met93SO to be
reduced back to methionine may lead to apoD aggregation. In AD,
enzymatic (lipoxygenase) and radical-mediated lipid peroxidation
is increased and this is reported to be associated with decreased
MSR activity [43]. This may explain why SDS-stable apoD
aggregates were detected in the GdnHCl-soluble fractions of the
hippocampus of AD patients in the present study. Alternatively,
the fact that amyloid plaques contain both oxidized lipids [44] and
apoD [45] might indicate that the aggregates are formed within
the plaques in a region that is devoid of active MSR.
The mechanism underlying the increase in apoD aggregation
that is associated with MetSO formation is not entirely clear.
Previous research indicates that even though the introduction of
an oxygen atom in the methionine side chain would be expected
to decrease the hydrophobicity of the protein (consistent with the
decrease in reversed-phase HPLC RT we have reported in the
present paper), this modification can induce structural changes
in the protein that increase the exposure of hydrophobic residues
[46,47]. On the basis of a previous research [29], this would be
predicted to induce local unfolding of the protein structure and
increase the propensity for apoD to self-associate.
The fact that apoD dimers that were formed concomitantly
with Met93 oxidation could be dissociated with 5 M urea indicates
that the aggregates are non-covalent. Although GdnHCl is often
considered to be a stronger denaturant than urea [48–51], it is
also known that the modes of denaturation action for GdnHCl
and urea are quite distinct. For example, GdnHCl (a salt) and
urea (uncharged) may be used to selectively assess hydrophobic
compared with electrostatic interactions. This difference has
been used previously to assess hydrophobic and electrostatic
interactions in coiled-coil analogues where, depending on the
relative number and type of electrostatic interactions present,
either compound can be observed to exhibit stronger denaturant
properties [52]. The fact that apoD dimerization is reversed by
5 M urea raises the possibility that apoD aggregation resulting
from MetSO formation is at least partly dependent on changes
in inter- or intra-molecular electrostatic interactions. The latter
interactions could lead to protein destabilization, whereas the
former could directly contribute to protein–protein interactions.
In summary, our present studies reveal that apoD Met93
selectively reduces HpETEs to their corresponding HETEs and
that this is associated with conversion of methionine into MetSO.
This activity represents a previously unknown function of apoD
that may contribute to its neuroprotective and lipid antioxidant
functions in the brain. In age-related pathological settings such as
AD, high levels of lipid peroxidation and/or decreased capacity
for MSR-mediated apoD MetSO reduction back to methionine
may contribute to the formation of apoD aggregates and their
deposition in amyloid plaques.
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MATERIALS AND METHODS
ApoD amino acid analysis using gas-phase HCl hydrolysis
ApoD amino acids that are stable under acid hydrolysis (excludes
cysteine, tryptophan and methionine) were analysed after 24 h
gas-phase hydrolysis in 6 M HCl at 110 ◦C, AccQTag labelling
and subsequent separation using an Acquity UPLC system
(Waters) with a 2.1 mm×150 mm, 1.7 μm, reversed-phase C18
column (Acquity UPLC BEH130, Waters). As asparagine and
glutamine are converted into aspartic acid and glutaminc acid
respectively, during acid hydrolysis the sum of these respective
amino acids is presented. All samples were analysed in duplicate
and results expressed as means. The coefficient of variation (CV)
for this amino acid analysis method was <2.0%.
Deglycosylation of apoD
ApoD N-glycans were removed using the Flavobacterium
meningosepticum PNGase F (peptide N-glycosidase F) provided
in a deglycosylation kit (New England BioLabs, catalogue number
P0705L) and according to the manufacturer’s instructions.
Generation of apoD and apoDM–A mutant stable CHO cell lines
CHO-K1 cells were obtained from the A.T.C.C. (Manassas,
VA, U.S.A.), cultured at 37 ◦C in a 5% CO2 atmosphere in
Dulbecco’s modified Eagle’s medium/Ham’s F12 medium (1:1
mixture) containing 10% (v/v) fetal bovine serum-supplemented
glutamax (2 mM). For the generation of apoD and apoDM–A mutant
over-expressing stable cell lines, CHO-K1 cells were transfected
with pcDNA3.1 wild-type apoD or apoDM–A mutant (1 μg) for
24 h using LipofectamineTM 2000 transfection reagent (4 μl/well
in a six-well plate), and stable transfectants were selected for
G418 (800 μg/ml) resistance by limiting dilution and screened
for apoD protein expression by Western blotting.
Figure S1 Characterization of recombinant apoA-I and apoD
(A) Recombinant human wild-type apoA-I was incubated in PBS (black line) or with 0.1 M
H2O2 (grey line) or 1.0 M H2O2 (broken line) in PBS for 1 h at 22◦C in the presence of 10 mM
EDTA. ApoA-I was then assessed by HPLC. (B) N-linked oligosaccharides were removed from
recombinant apoD using PNGase F with 1 h incubation at 37◦C (unless stated otherwise). Con,
control condition contains reaction buffer without incubation; HI PNG, heat-inactivated (5 min
at 95◦C) PNGase F; PNG, active PNGase F; 37◦C Con, reaction buffer only. Molecular mass is
given in kDa on the left-hand side.
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Figure S2 Generation of apoD CHO-K1 cell lines
CHO-K1 cells were transfected with pcDNA3.1 wild-type apoD or apoDM–A mutant (1 μg) and
stable transfectants were selected using G418 resistance. (A) Phase-contrast microscopy of
CHO-K1 (Con), wild-type apoD (apoD WT) and mutant apoDM–A (apoDM-A) cell lines. Scale bar
= 20 μm. (B) Western blot analysis of cellular and secreted apoD. Molecular mass is given in
kDa on the left-hand side.
Table S1 Clinical details of control and AD hippocampal samples
Frozen post-mortem hippocampal tissues were received from three control and three AD cases that were clinically and pathologically defined using National Institute on Aging-Reagan criteria. The
demographic and basic clinical data for these samples is provided. Con, control; PMI, post-mortem interval.
Case ID Gender Age (years) PMI (h) Brain pH Clinical cause of death AD duration (years) Braak Stage
Con 1 Female 78 11 6.3 Respiratory failure - -
Con 2 Male 69 13.5 6.7 Myocardial infarction - -
Con 3 Female 93 21 7.0 Cardiac failure - -
AD 1 Male 83 27 6.3 Cardiovascular accident 5 VI
AD 2 Female 84 9 6.3 Aspiration pneumonia 13 VI
AD 3 Female 83 7 6.2 Circulatory collapse 9 V
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Table S2 ApoD amino acid composition using gas-phase HCl hydrolysis
ApoD (0.5 mg/ml in PBS) was kept at 4◦C for 1 h (Con), or incubated at 37◦C for 1 h in the
absence (PBS) or presence (L-OOH) of 15s-HpETE (0.05 mg/ml). Protein was isolated from
lipid by ethanol precipitation and amino acids (excluding cysteine, tryptophan and methionine)
were determined using gas-phase acid hydrolysis and reversed-phase HPLC. Amino acid values
are provided as percentages.
Amino acid Theoretical Observed Con Observed PBS Observed L-OOH
Alanine 5.7 5.7 5.7 5.7
Arginine 2.2 2.5 2.5 2.5
Asparagine/aspartic acid 15.9 15.8 15.9 16.0
Glutamine/glutamic acid 10.7 11.1 11.3 11.2
Glycine 5.7 6.3 6.1 6.0
Histidine 4.5 4.4 4.4 4.4
Isoleucine 6.2 5.6 5.6 5.6
Leucine 8.4 8.6 8.5 8.6
Lysine 7.4 7.2 7.3 7.3
Phenylalanine 4.1 4.1 4.1 4.0
Proline 6.7 6.9 6.9 6.9
Serine 5.2 4.9 4.8 4.8
Threonine 6.2 5.8 5.9 5.9
Tyrosine 4.5 4.4 4.4 4.4
Valine 6.7 6.9 6.8 6.9
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